State Street Corp Sells 495,436 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

State Street Corp cut its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,556,283 shares of the biotechnology company's stock after selling 495,436 shares during the period. State Street Corp owned approximately 2.76% of Astria Therapeutics worth $17,135,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ATXS. FMR LLC raised its holdings in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company's stock worth $86,123,000 after purchasing an additional 1,767,714 shares during the period. RA Capital Management L.P. increased its position in shares of Astria Therapeutics by 1.2% in the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company's stock valued at $56,208,000 after buying an additional 61,457 shares in the last quarter. Vestal Point Capital LP raised its stake in Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company's stock worth $44,040,000 after buying an additional 750,000 shares during the period. Millennium Management LLC lifted its holdings in Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company's stock worth $16,763,000 after acquiring an additional 218,518 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in Astria Therapeutics by 15.4% in the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company's stock valued at $8,878,000 after acquiring an additional 130,000 shares during the period. Institutional investors own 98.98% of the company's stock.

Astria Therapeutics Stock Up 0.2 %

ATXS traded up $0.02 during trading hours on Wednesday, hitting $9.54. 314,237 shares of the company's stock were exchanged, compared to its average volume of 589,475. The stock has a market cap of $538.38 million, a price-to-earnings ratio of -4.56 and a beta of 0.67. Astria Therapeutics, Inc. has a 1-year low of $6.58 and a 1-year high of $16.90. The stock's 50-day moving average is $10.54 and its two-hundred day moving average is $10.72.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Oppenheimer raised their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $25.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.